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Background: The advent of novel molecular targets has dramatically changed the treatment landscape of 
lung cancer in recent years. Isochorismatase domain-containing protein 1 (ISOC1) has been reported as a 
potential biomarker in gastrointestinal cancer, while its function in lung cancer has not been determined. 
Methods: The expression levels and prognostic significance of ISOC1 were assessed using bioinformatic 
analysis. Overexpression of ISOC1 and miR-4633, and knockdown of ISOC1 in non-small cell lung cancer 
(NSCLC) cell lines were generated by lentiviral infection with overexpressed or shRNA plasmids. CRISPR/
Cas9 system was applied to knockout ISOC1 in A549 cells. The functions of ISOC1 and miR-4633 in lung 
cancer development were investigated using cell proliferation, migration, and invasion assays. Xenograft 
tumor growth assays in nude mice were further assessed the effect of ISOC1 in the tumorigenesis of NSCLC 
in vivo. Cell cycle distribution analysis was performed to uncover the underlying mechanism of ISOC1 
and miR-4633 in promoting NSCLC cell proliferation. Co-immunoprecipitation combined with mass 
spectrometry and RNA sequencing were performed to uncover the potential mechanism of ISOC1 in lung 
cancer development.
Results: Our results found that ISOC1 expression was upregulated in NSCLC tissues and that increased 
expression of ISOC1 was significantly associated with worse disease-free survival in NSCLC patients. 
Overexpression of ISOC1 could increase the proliferation, viability, migration, and invasion of NSCLC cells. 
Furthermore, miR-4633, located in the first intron of ISOC1, could also promote tumor cell progression and 
metastasis. Mice xenograft tumor assay showed that knockout of ISOC1 could significantly inhibit tumor 
growth in vivo. Besides, co-immunoprecipitation combined with mass spectrometry assay revealed that 
ISOC1 interacted with the proteins of DNA damage repair pathways and that upregulated ISOC1 expression 
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Introduction
Non-small cell lung cancer (NSCLC) accounts for 85% 
of all malignant lung tumors, with adenocarcinoma being 
the predominant histologic subtype of NSCLC (1). 
Novel treatment strategies based on targeted therapies 
and immunotherapies combined with platinum-based 
chemotherapy have produced improved survival benefits in 
NSCLC compared to traditional chemotherapy significantly 
prolonging the overall survival (OS) (2,3). To improve lung 
cancer patients’ prognosis, further efforts should be made 
to discover new molecular drivers and develop targeted 
therapies.
Isochorismatase domain-containing protein 1 (ISOC1), 
also known as CGI-111, belonging to the family of 
hydrolases, can catalyze the transformation of isochorismate 
into 2,3-dihydroxy-2,3-dihydrobenzoate and pyruvate, 
with another substrate-water (4). The human ISOC1 gene 
is located on chromosome 5q23.3 and encodes a protein of 
298 amino acids. Previous studies have reported that ISOC1 
is related to eye and testis development in animal models 
(5,6). ISOC1 has been reported to be involved in neutrophil 
development regulated by microRNA-130A (miRNA-
130A) in mice and humans (7). In addition to the above 
functions, ISOC1 was also found to play important human 
tumor biology roles. For instance, ISOC1 was identified 
to be deregulated in uterine leiomyoma (8) and was also 
proven to act as an estrogen-responsive gene, promoting 
breast cancer cells’ growth (9). Two recent studies revealed 
that knockdown of ISOC1 could impair tumorigenesis 
and gastrointestinal cancer progression through activating 
protein kinase B (Akt)/glycogen synthase kinase-3 beta 
(GSK-3β) pathway (10,11). However, the role of ISOC1 in 
lung carcinogenesis is still unknown. 
MicroRNAs (miRNAs) commonly lead to messenger 
RNA (mRNA) degradation and translation inhibition via 
binding to specific sequences. A number of miRNAs have 
been reported to be dysregulated in NSCLC and lead to the 
dysfunctions of oncogenic-related pathways (12). Intronic 
miRNAs, which are located on the intron of the host gene, 
can mediate and/or assist the host gene in performing 
various biological functions (13). The first intron of ISOC1 
encodes intronic miR-4633, was reported to be involved in 
the lung fibrosis mediated by transforming growth factor 
beta (TGF-β) and to contribute to the antitumor activity 
in sinonasal mucosal melanoma (14,15). Currently, limited 
knowledge on miR-4633 exists, and its function in NSCLC 
remains to be explored.
This study was a functional investigation of two lung 
cancer cell lines, A549 and H1299, with the aim to explore 
the roles of ISOC1 in the development and progression 
of NSCLC. Co-immunoprecipitation (Co-IP) combined 
with mass spectrometry (MS) and RNA sequencing were 
performed to uncover the potential mechanism of ISOC1 in 
lung cancer development. 
We present the following article in accordance with the 




Human NSCLC cell lines A549 and NCI-H1299, and 
human embryonic kidney cell line, HEK-293/HEK-293T, 
were preserved in the lab of Thoracic Surgery of Shanghai 
Pulmonary Hospital. NSCLC cells were cultured in 
RPMI-1640 medium supplemented with 10% fetal bovine 
serum (FBS, Gibco, USA), 100 U/mL penicillin, and 100 
mg/mL streptomycin (Gibco). HEK-293/HEK-293T 
could significantly increase the number of DNA damage lesions. RNA sequencing analysis showed that the 
downstream signaling pathways mediated by ISOC1 were mainly inflammation-related.
Conclusions: We demonstrated that ISOC1 and its intronic miR-4633, both of them could promote 
NSCLC cell proliferation, migration, invasion, and cell cycle progression. ISOC1 participates in DNA 
damage repair and inflammation to promote lung cancer development.
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cells were grown in complete Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% FBS. All cells 
were maintained at 37 ℃ in a humidified incubator with 
5% CO2. 
RNA extraction and quantitative real-time polymerase 
chain reaction (qRT-PCR)
Total RNA was extracted from cultured cells which were 
harvested with TRIzol reagent (Invitrogen, USA) to 
quantify the expression of relevant genes. The reverse 
transcription reactions were carried out according to 
the manufacturer’s protocol of commercially available 
kits (Vazyme, China). qRT-PCR was performed on a 
LightCycler 96 (Roche, Switzerland) and detected with 
THUNDERBIRD SYBR qPCR Mix (Toyobo, Japan). The 
primer sequences used in this study are listed in Table S1. 
The qPCR conditions were 95 ℃ for 3 min, and then 40 
cycles at 95 ℃ for 15 s and 60 ℃ for 45 s. The differences 
in mRNA expression were compared using the comparative 
cycle threshold (Ct) method. Beta-actin was detected as the 
endogenous control for ISOC1. 
Plasmid construction and lentivirus infection
To generate ISOC1 (ISOC1 OE) and miR-4633 stably 
overexpressed NSCLC cell lines, the full-length of ISOC1 
and miR-4633 were amplified from complementary DNA 
(cDNA) and genomic DNA (gDNA) from the NSCLC 
cell line A549 by PCR and were cloned into the pCDH-
CMV-MCS-EF1-GFP+Puro (CD513B) plasmid (System 
Biosciences, USA). To stably interfere with ISOC1 
expression, the short hairpin RNA (shRNA) sequences 
targeting ISOC1 were designed and cloned into the plasmid 
LentiLox 3.7 (pLL3.7) to knock down the expression of 
ISOC1 (ISOC1 KD). The CD513B empty vector (EV) 
and pLL3.7 EV were used as controls for CD513B-ISOC1 
and pLL3.7-shISOC1 (shISOC1-1 and shISOC1-2), 
respectively. Lentiviral production, collection, and infection 
were performed as described in previous studies (16). 
To silence ISOC1 expression at DNA level, clustered 
regularly interspaced short palindromic repeats and an 
associated protein-9 nuclease (CRISPR/Cas9) system was 
applied to knockout ISOC1 (ISOC1 KO) in A549 cells. To 
construct a single Cas-ISOC1-single guide RNA (sgRNA) 
vector, ISOC1 sgRNA was designed using the sgRNA 
design website (http://crispr.mit.edu/). The construction of 
the plasmid was conducted as previously reported (17). 
Dual-luciferase reporter assay
The 3'-untranslated region (3'UTR) of ISOC1 was cloned 
into the pGL3-promoter luciferase reporter plasmid 
(Invitrogen). HEK-293 cells were cultured in 24-well plates 
and transfected with 0.5 μg of pGL3-promoter constructs 
containing 3'UTR of ISOC1 or EV together with 0.3 μg 
CD513B-miR-4633 or EV plasmids using Lipofectamine 
2000 (Invitrogen) as the transfection reagent. After 36 h, the 
cell lysate was collected to determine the firefly and renilla 
luciferase signals using the dual-luciferase reporter assay 
system (Promega, USA).
Western blot analysis
Transfected cells were lysed and total proteins were 
extracted using cell lysis buffer for Western blot and 
immunoprecipitation (Beyotime Biotechnology, China). 
Equal amounts of proteins were separated by 10–12% 
SDS-PAGE and were then transferred onto polyvinylidene 
difluoride (PVDF) membranes (Millipore, USA). The 
membranes were blocked with tris-buffered saline (TBS) 
solutions (containing 5% fat-free milk powder and 10% 
Tween 20) at room temperature for 1 h and incubated 
with ISOC1 (1:1,000 dilution; Abcam, USA) or beta-actin 
(1:2,000 dilution; Abcam, USA) overnight at 4 ℃, followed 
with secondary antibody (1:5,000 dilution; Cell Signaling 
Technology, USA) at room temperature for 2 h. The blots 
were visualized using enhanced chemiluminescence (ECL) 
solutions and an imaging system (GE Healthcare, USA).
Cell proliferation assay
Cell Counting Kit-8 (CCK-8, Dojindo, Japan) assay 
was carried out to evaluate cell proliferation in different 
NSCLC cell lines, including the ISOC1 OE, KD, and KO 
groups. Approximately 1,500 cells/well were seeded into a 
96-well and cultured at 37 ℃ for 1 to 5 days. The medium 
was replaced, and 100 μL RPMI-1640 (containing 10% 
CCK-8 solution) was added before the test. After culturing 
at 37 ℃ for 1 h, the absorbances at 450 and 630 nm were 
measured. The ratio of optical density (OD) (450–630 nm) 
values achieved on the following days from the first day 
(fold change) was calculated to assess the ability of cell 
proliferation. 
Colony formation assay
For the colony formation assay, 250 cells/well were seeded 
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into 6-well plates in triplicate. After ten days of consecutive 
culture, the cells were fixed with 4% paraformaldehyde 
fix solution and stained with 1% crystal violet solution for 
1 h, and clones with more than 50 cells were included in the 
count.
Transwell migration and invasion assays
Cells were serum-starved for 24 h and suspended in 
serum-free medium. For migration assay, 20,000 cells in a 
200 μL medium were seeded into the upper chamber of a 
noncoated 8 μm-pore-size membrane (Corning, USA) in a 
24-well plate, and 600 μL complete medium was added to 
the lower chamber to induce cell migration. After 24–36 h 
of incubation, cells that adhered to the lower surface of 
the membrane were fixed with 4% paraformaldehyde and 
stained with 1% crystal violet before observation. For 
invasion assay, 30,000 cells in 200 μL serum-free medium 
were seeded into the upper chamber of an 8 μm-pore-size 
membrane coated with 0.2 mg/mL Matrigel (BD, USA) in 
a 24-well plate, and the lower chamber was infused with 
600 μL of complete medium to induce cell migration. The 
subsequent steps were similar to Transwell migration assay. 
Five fields were randomly chosen for cell counting.
Cell cycle analysis
Cells were collected and washed using phosphate-buffered 
saline (PBS) three times. The collected cells were fixed in 
5 mL 70% ethanol overnight at –20 ℃ and then washed 
with PBS. After that, cells were resuspended with 400 μL of 
staining solution, containing 20 μg/mL of propidium iodide 
(PI) and 90 μg/mL of RNase (Sangon Biotech, China) for 
30 min at 37 ℃. PI-stained cells were then analyzed using 
fluorescence-activated cell sorting (FACS; BD). At least 
10,000 cells were counted from each sample.
Tumor xenograft animal model
Male nude mice (4–6 weeks old) were purchased from Slac 
Laboratory Animals Center (Shanghai, China). Mice were 
randomly divided into different groups of 7 animals each and 
fed at the Animal Center of Shanghai Pulmonary Hospital 
for 1 week before operation. In the operation, 5×106 ISOC1 
wild-type (WT)/KO A549 cells were subcutaneously 
injected into the right flanks of nude mice. Mouse 
xenograft tumors were harvested 5 weeks later, and the 
tumor volume was calculated using the following formula: 
(the largest diameter × the smallest diameter2)/2 (18). 
Experiments were performed under a project license 
(No. K18-037) granted by Institutional Review Board 
of Shanghai Pulmonary Hospital, in compliance with 
institutional guidelines for the care and use of animals.
Co-IP combined with MS assay
The ISOC1-overexpressing plasmid with flag tag was 
transfected into the HEK293T cell line. The proteins 
were harvested using IP lysis buffer (CLB, Beyotime 
Biotechnology). The proteins were incubated with anti-
FLAG magnetic beads (Sigma-Aldrich, USA) overnight at 
4 ℃. The mixture of proteins and beads were washed three 
times with BC100 buffer (Beyotime Biotechnology). The 
obtained proteins were separated by 10% SDS-PAGE, and 
then detected by MS to identify the proteins interacting 
with ISOC1.
RNA sequencing
The total RNA was extracted from A549 cell line of the 
ISOC1 OE and KO groups, respectively. In preparation 
for subsequent sequencing, oligo-dT was used to capture 
mRNA, the mRNA was digested, and the barcodes were 
obtained. The sequencing was completed using an Illumina 
Hiseq2500 sequencer (Illumina, USA). The entire sequencing 
operation was carried out by Shanghai WeHealth BioMedical 
Technology Co., Ltd. (Shanghai, China). Pathway analysis of 
differently expressed genes (DEGs) was carried out using the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) tool 
(http://www.genome.jp/kegg).
DNA damage detection assay
A DNA damage quantitation kit (Dojindo) was used to 
complete the DNA damage detection assay. Cells were 
treated with cisplatin (20 μM) for 2 h to induce DNA 
damage, and then gDNA was extracted from cisplatin-
treated cells using a TIANamp Genomic DNA Kit 
(Tiangen, China). The number of DNA lesions in each 
cisplatin-treated sample per 100,000 bases was measured. 
The experiments were performed according to the 
manufacturer’s instructions.
Bioinformatic analysis 
The mRNA expression levels of ISOC1 in NSCLC and 
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normal lung tissues were obtained from UCSC Xena 
browser (https://xenabrowser.net/) based on the data from 
The Cancer Genome Atlas lung cancer (TCGA-LUNG) 
and Genotype-Tissue Expression (GTEx) project. The 
expression difference between tumor and normal samples 
was plotted using the R package (http://doi.org/10.5281/
zenodo.2074621). To assess the prognostic significance 
of ISOC1 in NSCLC, the Gene Expression Profiling 
Interactive Analysis (GEPIA, http://gepia.cancer-pku.cn/) 
website was applied to analyze the data of ISOC1 mRNA 
expression based on 982 samples from the TCGA-LUNG 
and GTEx project databases. 
Statistical analysis
Data are expressed as mean ± standard deviation, and 
independent Student’s t-tests were employed to compare 
the differences. Kaplan-Meier analysis was performed to 
generate survival curves based on the expression level of 
ISOC1, and log-rank test was carried out to assess the 
difference of survival curves between the different groups. 
Multivariate cox regression analysis was used to identify 
the independent risk factor for survival outcome. Survival 
curves and hazard ratios (HRs) were used to evaluate the 
prognostic importance of ISOC1 on disease-free survival 
(DFS) and OS in NSCLC patients. All statistical analyses 
were processed by SPSS statistics 17.0 (IBM Corp., USA). 
A P value <0.05 was considered to be statistically significant. 
Results
ISOC1 was upregulated in NSCLC and was significantly 
associated with poor DFS
To assess the expression of ISOC1 in NSCLC, a comparison 
of ISOC1 mRNA expression between 1,122 NSCLC tumor 
(stage I–IV) and 288 normal lung tissues obtained from 
the online UCSC Xena database was analyzed. The results 
showed that mRNA expression of ISOC1 was elevated in 
NSCLC tissues compared with normal tissues (adjusted 
P<0.001, Figure S1A). Survival curve analysis showed 
that higher mRNA expression of ISOC1 was significantly 
associated with a worse DFS (log-rank P=0.019; Figure 
S1B) but not significantly associated with OS (log-rank 
P=0.72; Figure S1C) in NSCLC patients. Multivariate cox 
regression analysis showed that elevated ISOC1 expression 
was an independent risk factor for a decreased DFS in 
NSCLC patients (HR =1.3, P=0.020; Figure S1B).
ISOC1 promoted NSCLC cell proliferation, migration, 
and invasion
To investigate the functions of ISOC1 in lung cancer 
development, cell proliferation, migration, and invasion 
assays were carried out in NSCLC cell lines, A549 and 
H1299. Western blot and qRT-PCR assays were used 
to assess the protein and mRNA expression of ISOC1 
in OE (ISOC1), KD (shISOC1-1 and shISOC1-2), and 
KO (ISOC1-KO) groups. The results confirmed that the 
expression of ISOC1 was successfully elevated in the OE 
group, downregulated in the KD group, and absent in the 
KO group in A549 (Figure 1A) and H1299 (Figure S2A) 
cells. 
CCK-8 assay was performed to determine the effect of 
ISOC1 on NSCLC cell proliferation. Forced expression 
of ISOC1 significantly promoted the proliferation of A549 
and H1299 cell lines compared with the control groups, 
while cell proliferation was significantly decreased in the 
KD or KO groups (P<0.01, Figure 1B and Figure S2B). 
Transwell assays were carried out to evaluate the migration 
and invasion ability of ISOC1 OE, KD, and KO tumor 
cells. The results of migration assays showed that the 
ability of NSCLC cell overexpressing ISOC1 to migrate 
was increased as compared with the control group (P<0.05). 
On the other hand, cell migration was restricted when the 
expression of ISOC1 was blocked (P<0.05). Consistently, 
results of invasion assay showed that the number of invading 
cells in the OE group was increased but was decreased 
when ISOC1 expression was impaired (P<0.05, Figure 1C 
and Figure S2C). Furthermore, as shown in Figure 1D and 
Figure S2D, ISOC1 overexpression promoted NSCLC cell 
colony formation compared with the control group (P<0.01), 
while ISOC1 knockdown inhibited cell colony formation in 
A549 and H1299 cell lines (P<0.05). 
As ISOC1 expression was elevated in NSCLC, WT 
and ISOC1 KO A549 cells were used for xenograft tumor 
growth assays in nude mice to further assess the effect of 
ISOC1 in the tumorigenesis of NSCLC in vivo. The results 
showed that ISOC1 deficiency led to a significant decrease of 
tumor volume compared to WT mice. Hematoxylin-eosin 
(HE)-stained tumor section confirmed that the xenograft 
tumor harvested in this study was lung adenocarcinoma 
(P<0.05, Figure 1E). 
miR-4633 functioned as a tumor-promoter in NSCLC
To determine whether intronic miR-4633 regulates its host 
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Figure 1 Effects of ISOC1 on NSCLC cell progression, migration, and invasion. (A) OE, KD (shISOC1), and KO efficiency of ISOC1 was 
determined by Western blot and qRT-PCR. (B) CCK-8 cell proliferation assays in ISOC1 OE, KD, and KO A549 cells from days 1 to 5. 
(C) Transwell migration and invasion assays in ISOC1 OE, KD, and KO A549 cells (×200). Cells were stained with crystal violet. (D) Effects 
of OE, KD and KO of ISOC1 on colony formation in A549 cell line. (E) Tumor xenograft assay performed in the ISOC1 KO group and 
hematoxylin-eosin staining confirmed tissues as tumorous (×400). The number of mice in each group was 7. Three mice in the ISOC1-KO 
group died 3 weeks after tumor implantation and no suspicious tumor tissues were found subcutaneously. *, P<0.05; **, P<0.01; ***, P<0.001. 
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ISOC1 gene, a dual-luciferase reporter assay was applied in 
the HEK293 cell line. The results showed that ISOC1 was 
not the target of miR-4633 (P>0.05, Figure 2A). As miR-
4633 showed no apparent effect on regulating its host gene, 
ISOC1, further investigations on the role of miR-4633 in 
NSCLC tumorigenesis were performed. The results ensured 
that the expression of miR-4633 was successfully upregulated 
in both A549 and H1299 cell lines (P<0.001, Figure 2B and 
Figure S3A); furthermore, the overexpression of miR-4633 
could promote cell proliferation (P<0.001, Figure 2C and 
Figure S3B), and increase the abilities of cell migration and 
invasion in A549 and H1299 cell lines (P<0.05, Figure 2D 
and Figure S3C). The results of colony formation assay also 
showed that NSCLC cells exhibited an enhanced capacity for 
colony formation when miR-4633 expression was elevated 
(P<0.05, Figure 2E and Figure S3D). 
ISOC1 and miR-4633 promoted cell cycle progression in 
NSCLC
To elucidate the underlying mechanism of ISOC1 and miR-
4633 in promoting NSCLC cell proliferation, cell cycle 
distribution analysis was performed using flow cytometry. 
The results showed that the proportion of cells in the S 
and G2/M phases was significantly increased in the ISOC1 
OE groups, while the proportion of G1-phase cells were 
significantly decreased (P<0.001, Figure 3A and Figure S4A); 
moreover, comparison with the control groups suggested 
that knockdown of ISOC1 could induce G1 arrest (P<0.01, 
Figure 3B and Figure S4B). The results of ISOC1 knockout 
also produced G1 arrest and a decreased proportion of G2/
M-phase cells (P<0.05, Figure 3C). Furthermore, when 
miR-4633 was overexpressed, a decreased proportion of 
G1-phase cells and an increased proportion of S-phase cells 
were observed in both cell lines (P<0.05, Figure 3D and 
Figure S4C).
ISOC1 interacted with molecules of DNA damage repair 
and cell cycle arrest pathway
To investigate the potential mechanism of ISOC1 involved 
in NSCLC development, CO-IP and MS assay was carried 
Figure 2 miR-4633 promoted cell viability in NSCLC. (A) Relative luciferase activity of WT ISOC1-3'UTR by miR-4633. (B) Forced 
expression of miR-4633 in A549 cells was assessed by qRT-PCR. (C) Effects of miR-4633 on A549 cell proliferation was examined by CCK-
8 assay. (D) Transwell assay was used to assess effects of miR-4633 on A549 migration and invasion (×200). Cells were stained with crystal 
violet. (E) Colony formation assays in A549 cells infected with EV or miR-4633 lentivirus. *, P<0.05; **, P<0.01; ***, P<0.001. WT, wild-
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Figure 3 Effects of ISOC1 and miR-4633 on cell cycle distribution. (A) ISOC1 OE in A549 cells caused an increases cell accumulation in S 
and G2/M phases. (B) ISOC1 knockdown induced G1 arrest in A549 cells. (C) ISOC1 deficiency caused decrease of G2/M phase cells in the 
A549 cell line. (D) miR-4633 promoted G1/S progression in the A549 cell line. *, P<0.05; **, P<0.01; ***, P<0.001. OE, overexpression; KD, 





1452 Shi et al. ISOC1 promotes lung cancer development
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2021;10(3):1444-1456 | http://dx.doi.org/10.21037/tlcr-21-219
out to identify the proteins that interact with ISOC1. The 
results showed that many proteins involved in the DNA 
damage repair pathway (TP53, PARP1, SFPQ, and NONO) 
and cell cycle arrest were detected (data not shown). To 
confirm that ISOC1 participates in DNA damage repair, 
DNA of cisplatin-treated NSCLC cells was extracted from 
different groups and detected by DNA damage detection 
assay. The results showed that overexpression of ISOC1 
resulted in an increased number of DNA damage lesions 
(P<0.01), while the DNA damage sites were decreased 
when the expression of ISOC1 was downregulated or absent 
(P<0.05, Figure 4A).
ISOC1 is involved in inflammatory signaling pathway
To further explore the downstream signaling pathways 
mediated by ISOC1, RNA sequencing was performed 
in A549 cell lines of the ISOC1 OE and KO groups. To 
reveal the potential signaling pathways regulated by ISOC1, 
KEGG pathway analysis was carried out based on the 
differential expression of genes in the different groups. The 
results identified several inflammation-related pathways 
including IL-17 signaling pathway, TNF signaling pathway, 
cytokine-cytokine receptor interaction, NF-kappa B 
signaling pathway, chemokine signaling pathway, and others 
(Figure 4B,C).
Discussion
Due to its high morbidity and mortality, lung cancer 
remains a great threat to human health. The therapeutic 
landscape of NSCLC has been profoundly expanded by 
the exploration of specific driver alterations and the use 
of immune checkpoint inhibitors (19). However, cancer 
development and progression is a complex process involving 
a variety of genes and signaling pathways. The efforts to 
study multiple biomarkers, including their interactions, have 
contributed to uncovering common targets and enhancing 
therapeutic efficiency. ISOC1, along with its homolog 
ISOC2, have not yet been extensively characterized. 
Previous studies have revealed that ISOC2 may induce 
cell development by deregulating the activity of tumor-
suppressor p16 (INK4a), and may promote tumor growth 
and differentiation through binding to the inhibitor of 
histone acetyltransferases and histone deacetylases (20,21). 
These previous findings suggest that ISOC2 functions as 
an oncogene in tumorigenesis, and that ISOC1, which 
belongs to the same family, may play a similar role in tumor 
progression. Studies have reported that the knockdown of 
ISOC1 can lead to the upregulation of tumor-suppressive 
activity in breast cancer, pancreatic cancer, and colon 
cancer (9-11), but, to the best of our knowledge, few, if any 
research, has discussed its effect on lung cancer.
To determine the function of ISOC1 in lung cancer 
development, this study was conducted to clarify the role of 
ISOC1 in promoting NSCLC development and progression. 
This study demonstrated that the expression of ISOC1 
was significantly increased in malignant lung tumors than 
normal lung samples, and a higher expression of ISOC1 was 
associated with worse DFS and a decreased 5-year survival 
rate. Function investigation showed that elevated expression 
of ISOC1 could significantly increase cell proliferation and 
colony formation viability of NSCLC cell lines, and also 
promote cell migration and invasion in vitro. However, 
these tumor-promoting phenotypes were suppressed when 
ISOC1 was silenced. In vivo, xenograft tumors’ growth was 
significantly inhibited when ISOC1 was knocked out using 
the CRISPR/Cas9 system. These data indicated that ISOC1 
exhibited a tumor-promoting function in lung cancer 
development and progression both in vitro and in vivo. Cell 
cycle distribution assays illustrated that overexpressing 
ISOC1 led to a marked increase in the proportion of cells in 
the M and G2/S phases, suggesting that ISOC1 may play an 
essential role in the regulation of the cell cycle and promote 
cell cycle progression; while ISOC1 knockdown or knockout 
induced G1 arrest, constituting an impediment to the G2/M 
transition protein synthesis and can restrict tumorigenesis 
in vitro. Co-IP and MS assays revealed that ISOC1 could 
interact with the DNA damage repair pathway, and further 
investigation confirmed that overexpression of ISOC1 led 
to increased DNA damage sites. Dysregulation in the DNA 
damage repair pathway induces the accumulation of genetic 
alteration and facilitates carcinogenesis in lung cancer (22). 
RNA sequencing results showed that the main downstream 
signaling pathway mediated by ISOC1 was inflammation-
related pathways, including IL-17 signaling pathway, 
TNF signaling pathway, cytokine-cytokine receptor 
interaction, NF-kappa B signaling pathway, chemokine 
signaling pathway, and others. Taken together, these results 
indicate that ISOC1 interacts with molecules of DNA 
damage repair pathway and cell cycle arrest to participate 
in inflammation response. One recent study has shed light 
on the immune-stimulatory effects of ISOC1 on IL-17 
production in memory T cells (23), and other researches 
have also implicated the association between ISOC1 and 
inflammation in neutrophil development and Staphylococcus 
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Figure 4 ISOC1 was involved in DNA damage and inflammation-related pathways. (A) Quantitation of the number of DNA damage sites 
in A549 cells treated with cisplatin (20 μM) and detected 2 h thereafter. (B) KEGG pathway enrichment analysis results based on the RNA 
sequencing assay in A549 cells with ISOC1 OE. (C) KEGG pathway enrichment analysis results detected by the RNA sequencing assay in 
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aureus infection (7,24), which could further confirm our 
RNA sequencing data.
Numerous studies have focused on the connection 
between DNA damage and inflammation, because potential 
imbalances within the DNA damage repair pathway can 
promote an inflammatory microenvironment, initiating 
cancer and facilitating cancer cell growth (25-27). For 
example, the cGAS-cGAMP-STING pathway mediates the 
balance between antitumor immunity and inflammation-
driven carcinogenesis when DNA damage occurs (28). Our 
collective findings indicate that ISOC1 is involved in the 
DNA damage repair pathway and mediates inflammation-
re la ted  s igna l ing  pa thways  to  promote  NSCLC 
development, and consequently contributes to lung 
tumorigenesis and cancer cell survival. Therefore, ISOC1 
may engage in connecting DNA damage to inflammation 
and cancer.
A number of miRNAs have been reported to be 
associated with lung cancer development and behavior (25). 
Nearly half of miRNAs are classified as intronic miRNAs 
according to their genomic location (13). It is estimated 
that approximately 20% of host genes are targeted by 
their own intronic miRNAs and are affected by mRNA 
stability. Previous evidence supports the hypothesis that 
some miRNAs are co-expressed with their host genes in 
cancer, acting synergistically or antagonistically (13,26). 
miR-4633 is encoded in the first intron of ISOC1, and 
it has been previously studied only in sinonasal mucosal 
melanoma and lung fibrosis. Here, we found that miR-
4633 played an important role in NSCLC tumorigenesis 
itself instead of directly regulating the expression of 
ISOC1. miR-4633 showed to promote cell proliferation, 
metastasis, and induce G1-S transition in NSCLC, which 
indicated that miR-4633 also acted as a tumor-promoting 
factor in lung cancer development. According to these 
findings, we hypothesized that miR-4633 and ISOC1 
might cooperate to enhance lung cancer development 
and progression. Zou et al. found that miR-4633 was 
related to melanoma metastasis, and overexpression of 
miR-4633-5p, one of the mature forms of miR-4633, 
inhibited the activation of the PI3K/Akt pathway and its 
downstream molecule GSK-3βSer9 in melanoma cells (14). 
Surprisingly, Gao et al. recently reported that ISOC1 
deficiency could partially activate the Akt/GSK-3β pathway 
and inhibit cell growth in colon cancer (11). Activating Akt 
could phosphorylate a serine residue (Ser-9) on GSK-3β, 
which could inhibit kinase activity and ultimately suppress 
tumor growth (27). These studies indicated that ISOC1 and 
miR-4633 might function synergistically through inhibiting 
the activation of GSK-3βSer9, with GSK-3β having been 
identified as a tumor promoter in most cancer types, 
including NSCLC (28). More comprehensive and in-depth 
studies would be needed to assess this relationship in our 
future work. Our RNA sequencing findings also showed 
that ISOC1 regulated PI3K/Akt pathway in lung cancer. 
However, a number of inflammation-related pathways were 
reported to affect lung cancer patients’ prognosis (29), 
and were revealed to be more significant than PI3K/Akt 
pathway in NSCLC development mediated by ISOC1 in 
this study. Further investigation should be performed in the 
near future.
In  conclus ion,  our  present  s tudy showed that 
upregulation of ISOC1 was observed in the NSCLC tumor 
tissues and was associated with shorter survival. ISOC1 
and its intronic miR-4633, both of them could promote 
NSCLC cell proliferation, migration, invasion, and cell 
cycle progression. ISOC1 interacts with DNA damage 
repair pathway and mediates inflammation-related signaling 
pathways to promote lung tumorigenesis and cancer cell 
survival.
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Table S1 Primer sequences used in this study.
Primer name Primer sequence (5'-3')
ISOC1 forward primer (qPCR) GAGATTCCCGGAGTCAGGAG
ISOC1 reverse primer (qPCR) TCGTGGTCACTATGATCCCG
miR-4633-5p primer (RT) GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACGAGGAGCT
miR-4633-3p primer (RT) GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACTGCATATG
miR-4633 forward primer (qPCR) CAGTGCGTGTCGTGGAGT
miR-4633-5p reverse primer (qPCR) ACACTCCAGCTGGGATATGCCTGGCTAG
miR-4633-3p reverse primer (qPCR) ACACTCCAGCTGGGAGGAGCTAGCCAGGCA
β-actin forward primer (qPCR) AGAAGGATTCCTATGTGGGCG
β-actin reverse primer (qPCR) GGATAGCACAGCCTGGATAGCA
U6 forward primer (qPCR) CTCGCTTCGGCAGCACA
U6 reverse primer (qPCR) AACGCTTCACGAATTTGCGT
CD513B-ISOC1 forward primer TCTAGAGCCACCATGGCGGCTGCGGAGCCGGCGGT
CD513B-ISOC1 reverse primer GGATCCCTACTTATCGTCGTCATCCTTGTAATCTACTTTGGAAAGCAGACCCG
CD513B-miR-4633 forward primer CACAAATGCGTGTGGGAGCGTCACTTACAGCCGAACACAG
CD513B-miR-4633 reverse primer CCACACGCATTTGTGGCGGAGACTTGCCATGTAACCTGCA
pLL3.7-shISOC1-1 forward primer TGTACTTCCAAAGACCAAGTTTTTCAAGAGAAAACTTGGTCTTTGGAAGTATTTTTTC
pLL3.7-shISOC1-1 reverse primer TCGAGAAAAAATACTTCCAAAGACCAAGTTTTCTCTTGAAAAACTTGGTCTTTGGAAGTACA
pLL3.7-shISOC1-2 forward primer TGCCTCACAATGTTGTCCACTTATTCAAGAGATAAGTGGACAACATTGTGAGGTTTTTTC
pLL3.7-shISOC1-2 reverse primer TCGAGAAAAAACCTCACAATGTTGTCCACTTATCTCTTGAATAAGTGGACAACATTGTGAGGCA
ISOC1 3'-UTR forward primer GTGTAATTCTAGACATATGGGGCCCGACATTTGAAGAACTGGTATGCTACTCACTG
ISOC1 3'-UTR reverse primer CCCCGACTCTAGAGAATTCAATTACTTTAATATAAAAGACAGCAGTTTCACATTTCAC
ISOC1 sgRNA forward primer CGACATGCACCGCAAATTCGGTTTTAGAGCTAGAAATAGCAAGTTAA
ISOC1 sgRNA reverse primer ACCGAATTTGCGGTGCATGTCGCAAACAAGGCTTTTCTCCAAGG
Supplementary
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Figure S1 ISOC1 expression was elevated in NSCLC. (A) The expression level of ISOC1 mRNA in NSCLC tumor tissues (n=1,122) and 
normal lung samples (n=288). Analysis of ISOC1 expression were processed with the data obtained from TCGA and GTEx database using 
UCSC Xena platform. The horizontal line represents the mRNA expression level [log2 (TPM + 0.001)]. (B) Disease-free survival curve 
analyses for NSCLC patients based on the expression level of ISOC1 mRNA. (C) Overall survival curve analyses for NSCLC patients based 
on the expression level of ISOC1 mRNA. TCGA, The Cancer Genome Atlas; GTEx, Genotype-Tissue Expression; TPM, transcripts per 
million; HR, hazard ratio. 
Figure S2 Effects of ISOC1 on H1299 cell progression, migration, and invasion. (A) OE and KD (shISOC1-1 and shISOC1-2) efficiency 
of ISOC1 was determined by Western blot and qRT-PCR. (B) CCK-8 cell proliferation assays in ISOC1 OE and KD H1299 cells from 
days 1 to 5. (C) Transwell migration and invasion assays in ISOC1 OE and KD H1299 cells (×200). Cells were stained with crystal violet. 
(D) Effects of ISOC1 OE and KD on colony formation in the H1299 cell line. *, P<0.05; **, P<0.01; ***, P<0.001. OE, overexpression; KD, 
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Figure S3 miR-4633 promoted cell viability in the H1299 cell line. (A) Forced expression of miR-4633 in H1299 cells was assessed by qRT-
PCR. (B) Effects of miR-4633 on H1299 cell proliferation was examined by CCK-8 assay. (C) Transwell assay was used to assess the effects 
of miR-4633 on H1299 migration and invasion (×200). Cells were stained with crystal violet. (D) Colony formation assays in H1299 cells 
infected with EV or miR-4633 lentivirus. *, P<0.05; ***, P<0.001. EV, empty vector. 
Figure S4 Effects of ISOC1 and miR-4633 on H1299 cell cycle distribution. (A) ISOC1 OE H1299 cells caused an increase of cell 
accumulation in S and G2/M phases. (B) ISOC1 KD H1299 cell line induced G1 arrest. (C) miR-4633 promoted G1/S progression in the 
H1299 cell line. *, P<0.05; **, P<0.01; ***, P<0.001. OE, overexpression; KD, knockdown; EV, empty vector; N.S., not significant. 
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